COMMUNIQUÉS West-GlobeNewswire

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
05/06/2024
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive [...]
Immutep successfully completes institutional placement and institutional component of entitlement offer
05/06/2024
Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP) ( Immutep or the Company ) is pleased to announce the successful completion of its institutional placement ( [...]
Curium Adds the Institut Laue-Langevin Reactor to Global Irradiation Portfolio to Ensure Continuous Supply of Lutetium-177 to Benefit More Than 100,000 Cancer Patients Over the Next 5 Years
05/06/2024
PARIS, June 05, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has signed a long-term partnership with the Institut Laue-Langevin (ILL) for irradiation services at their [...]
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
05/06/2024
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet [...]
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
05/06/2024
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% [...]
Ex dividend NOK 0.50 today
05/06/2024
The shares in Vistin Pharma ASA will be traded ex dividend NOK 0.50 as from today, 05.06.2024.
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis
05/06/2024
New data from the ELATIVE ® Phase III trial show 70% of patients treated with elafibranor achieved composite endpoint of slowing disease progression measured by biochemical response after 78-weeks Data from the itch [...]
Ipsen présente de nouvelles données sur l’efficacité à long terme d’elafibranor et la qualité de vie liée aux démangeaisons chez les patients atteints de cholangite biliaire primitive
05/06/2024
De nouvelles données de l’essai ELATIVE ® de Phase III révèlent que 70 % des patients traités par elafibranor ont atteint le critère d’évaluation composite du ralentissement de la progression de la maladie, mesuré par [...]
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant
05/06/2024
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant At the American Transplant Congress 2024 (June 1-5 Philadelphia) Nantes, [...]
OSE Immuno et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénale
05/06/2024
OSE Immunotherapeutics et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénale Au congrès 2024 [...]
Addex Convenes Annual General Meeting 2024
05/06/2024
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
05/06/2024
Saint-Herblain (France), June 5, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Combined General Meeting (“ [...]
Valneva annonce la mise à disposition des documents préparatoires à son Assemblée Générale Mixte et une évolution de son équipe de direction
05/06/2024
Saint-Herblain (France), 5 juin 2024 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA) (la « Société »), société spécialisée dans les vaccins, a annoncé aujourd’hui la mise à disposition des documents préparatoires à [...]
Fortrea cède ses activités Endpoint Clinical et Patient Access à Arsenal Capital Partners
05/06/2024
DURHAM, Caroline du Nord, 05 juin 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq : FTRE), un organisme de recherche sous contrat (« ORC ») de premier plan au niveau mondial, a annoncé aujourd’hui avoir finalisé la cession des [...]
Jushi Holdings Inc. Announces Voting Results of Annual Meeting
04/06/2024
BOCA RATON, Fla., June 04, 2024 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Corporation”) (CSE: JUSH) (OTCMKTS: JUSHF), a vertically integrated, multi-state cannabis operator, announced the voting results [...]
Annexon Announces Proposed Public Offering of Common Stock
04/06/2024
BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical [...]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/06/2024
BOSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments
04/06/2024
VIENNA, Austria, June 04, 2024 (GLOBE NEWSWIRE) -- QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced today that the company has [...]
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders
04/06/2024
TORONTO and HAIFA, Israel, June 04, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company developing [...]

Pages